Suraksha Diagnostic Limited has informed the Exchange about Investor Presentation
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suraksha Diagnostic reported FY26 revenue of ₹3,136 million, up 23% YoY, with EBITDA growing 16% to ₹986 million. Q4 EBITDA rose 26% YoY to ₹252 million. However, EBITDA margins compressed from 33.8% in FY25 to 31.8% in FY26 due to ongoing investments in new centre expansion and pre-operative expenses. PAT grew only 1.4% to ₹314 million as higher depreciation (+17%) and finance costs (+50%) offset EBITDA growth. The company added 20 centres since its December 2024 IPO, taking total to 68 diagnostic centres. Mature centres (over 2 years old) deliver 36-37% EBITDA margins versus overall 31.8%, indicating significant margin improvement potential as newer centres scale up. The company also acquired 63% stake in Fetomat Wellness (fertility clinics) and launched a Genomics vertical.
Strong revenue growth but margin compression concerns remain. The gap between mature centres (36-37% margins) and overall margins (31.8%) signals significant upside as newer centres mature and reach profitability benchmarks.